CEO Pleads Guilty to Misbranding Charge Under Park Doctrine for Misrepresentation of Drug’s Safety Risks

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

CEO Pleads Guilty to Misbranding Charge Under Park Doctrine for Misrepresentation of Drug’s Safety Risks

Prosecutors Allege That Company’s Medical Affairs Manager Deceived Massachusetts Medicaid Agency

Dennis Tosh

July 9, 2020 at 12:53 PM EST

The chief executive officer (CEO) of a pharmaceutical company has pleaded guilty to a federal misdemeanor misbranding charge related to allegations that other company officials misrepresented the safety risks of one of the firm’s pharmaceutical products in an effort to obtain a place for the drug on a state Medicaid program’s formulary (United States v. Thaxter, No. 1:20-cr-00... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

CEO Pleads Guilty to Misbranding Charge Under Park Doctrine for Misrepresentation of Drug’s Safety Risks

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT